FDA's Concerns With Unapproved and Compounded GLP-1 Drugs

The FDA has directly warned that unapproved versions of GLP-1 drugs, including semaglutide and tirzepatide, carry real, documented risks, since they haven't undergone the agency's standard review for safety, effectiveness, and quality.

Real, Documented Adverse Event Numbers

As of May 31, 2026, the FDA had received 990 adverse event reports associated with compounded semaglutide, and more than 730 associated with compounded tirzepatide.

Counterfeit and Fraudulent Products

The FDA has confirmed real cases of counterfeit Ozempic and fraudulent compounded products, some labeled with pharmacy names that don't actually exist.

Real Warning Signs Worth Knowing

Prices that seem too good to be true, no licensed-physician screening, and packaging inconsistencies are all real, documented red flags the FDA has specifically outlined.

Related Reading

Retatrutide: The Investigational "Triple Agonist" Drug Explained

Does GLP-1 Cause Hair Loss?

Can GLP-1 Medications Help With Alcohol Use Disorder?

Foundayo: What to Know About the New Oral GLP-1 Pill

For the full GLP-1 knowledge base, explore DietApp's GLP-1 Tracker hub